Yang Yanping, Walsh Christopher E
Department of Medicine, Mt. Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA.
Mol Ther. 2005 Dec;12(6):1006-12. doi: 10.1016/j.ymthe.2005.09.006. Epub 2005 Oct 12.
RNA repair or reprogramming is a new avenue for human gene therapy. Unlike conventional gene therapy, in which exogenous cDNAs are introduced into cells, RNA repair approaches, which are based on spliceosome-mediated pre-mRNA trans-splicing, trans-splicing ribozymes, and tRNA-splicing endonuclease, allow the correction of endogenous RNA species. Recently published accounts that in vivo phenotypic correction of a variety of inherited diseases can be achieved by RNA repair are encouraging. Nevertheless, the science of RNA repair for treatment of human diseases is just beginning and faces several scientific and technical challenges that must be addressed and surmounted. In this review, we summarize recent advances in spliceosome-mediated pre-mRNA trans-splicing. We also provide an update on the progress of this emerging technology toward the development of molecular therapy and diagnosis for human diseases and discuss the outstanding issues and challenges confronting RNA therapeutics.
RNA修复或重编程是人类基因治疗的一条新途径。与将外源性cDNA导入细胞的传统基因治疗不同,基于剪接体介导的前体mRNA反式剪接、反式剪接核酶和tRNA剪接内切酶的RNA修复方法能够校正内源性RNA种类。最近发表的关于通过RNA修复可实现多种遗传性疾病的体内表型校正的报道令人鼓舞。然而,用于治疗人类疾病的RNA修复科学才刚刚起步,面临着一些必须解决和克服的科学技术挑战。在本综述中,我们总结了剪接体介导的前体mRNA反式剪接的最新进展。我们还提供了这项新兴技术在人类疾病分子治疗和诊断发展方面的进展更新,并讨论了RNA治疗学面临的突出问题和挑战。